Eisai's Perampanel Oral Suspension Nominated for Priority Review in China

On March 17, 2022, the CDE website announced that Eisai's Perampanel Oral Suspension is proposed for inclusion in the priority review. It is intended for treating partial-onset seizures with or without secondary generalization and primary generalized tonic-clonic seizures in epilepsy patients aged 12 years and above.